구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PLD (Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin (PLD)) AGO Research GmbH·Ovarian Neoplasms 177 trials·t½ 3 h | |
|---|---|---|
Overview Program | Pegylated liposomal doxorubicin (PLD) | mycophenolate mofetil |
Overview Company | AGO Research GmbH | Amsterdam Molecular Therapeutics |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Ovarian Neoplasms | FRα |
Overview Indication | Ovarian Neoplasms; Fallopian Tube Neoplasms | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
MoA Mechanism | target of HMB action and demonstrate that HMB preserves muscle homeostasis through coordinated modulation of anabolic signaling | Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite |
MoA Biomarker | biomarkers (blood eosinophil levels and lung function) | CD20+ B cell levels rapidly declining to extremely low |
PK/PD Half-life | 3 h | — |
PK/PD Species | Mouse | Mouse, xenografts, which corroborat |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | PK | pharmacokinetic |
Toxicology Species | Mouse | Mouse |
Toxicology Animal (cat.) | Mouse | Mouse |
Toxicology Major finding | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… | pneumonitis with high serum and bronchoalveolar viral loads, herpesvirus reactivation compa |
Clinical Safety signal | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… | pneumonitis with high serum and bronchoalveolar viral loads, herpesvirus reactivation compa |
Clinical Reported PFS | 8.2 | 104 |
Clinical Reported OS | 14.9 | 0.83 |
Clinical Result source | ClinicalTrials.gov NCT03164980 | ClinicalTrials.gov NCT00057954 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03164980 | NCT00057954 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PLD (Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin (PLD)) AGO Research GmbH·Ovarian Neoplasms 177 trials·t½ 3 h | |
|---|---|---|
Overview Program | Pegylated liposomal doxorubicin (PLD) | mycophenolate mofetil |
Overview Company | AGO Research GmbH | Amsterdam Molecular Therapeutics |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Ovarian Neoplasms | FRα |
Overview Indication | Ovarian Neoplasms; Fallopian Tube Neoplasms | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational |
MoA Mechanism | target of HMB action and demonstrate that HMB preserves muscle homeostasis through coordinated modulation of anabolic signaling | Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite |
MoA Biomarker | biomarkers (blood eosinophil levels and lung function) | CD20+ B cell levels rapidly declining to extremely low |
PK/PD Half-life | 3 h | — |
PK/PD Species | Mouse | Mouse, xenografts, which corroborat |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | PK | pharmacokinetic |
Toxicology Species | Mouse | Mouse |
Toxicology Animal (cat.) | Mouse | Mouse |
Toxicology Major finding | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… | pneumonitis with high serum and bronchoalveolar viral loads, herpesvirus reactivation compa |
Clinical Safety signal | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… | pneumonitis with high serum and bronchoalveolar viral loads, herpesvirus reactivation compa |
Clinical Reported PFS | 8.2 | 104 |
Clinical Reported OS | 14.9 | 0.83 |
Clinical Result source | ClinicalTrials.gov NCT03164980 | ClinicalTrials.gov NCT00057954 |
Clinical Program phase | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03164980 | NCT00057954 |
추천 비교
추천 비교